Polygenetics

Polygenetics, Inc. was a biotechnology company specializing in the development of advanced polymer-based drug delivery platforms. The company's core technology, the Cavilink platform, utilized highly porous polymer microspheres for the controlled release of therapeutic agents, particularly in the field of embolotherapy. Polygenetics also developed the MD Turbo, a breath-triggered inhalation device designed to improve the delivery and dosing of respiratory medications. The company established significant partnerships, including a major licensing agreement with Boston Scientific for its microsphere technology and a collaboration with TEAMM Pharmaceuticals for its inhalation platform. Although the company is no longer active, its innovations in porous polymers and device-triggered delivery significantly contributed to the field of targeted therapeutics.